Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and Hepatitis C.
Kennet, as the new General Manager of Gilead Sciences’ Canadian affiliate, what mandate was entrusted to you upon your appointment in January 2017?
"A key challenge we have – at Gilead but also as an industry – is how to expedite access to medicines for patients in Canada."
